Header Logo

Connection

DANIEL D KARP to Pyrazines

Back to Details
This is a "connection" page, showing publications DANIEL D KARP has written about Pyrazines.
DANIEL D KARP
Connection Strength
0.149
Pyrazines
  1. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
    View in: PubMed
    Score: 0.149
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.